

#### **India I Equities**

### Artificial Leather Company Update

Change in Estimates ☑ Target ☑ Reco □

11 November 2020

### **Mayur Uniquoters**

Good recovery in domestic auto/exports, footwear to follow; Buy

Mayur's Q2 was a mixed-bag (revenue/PBT/PAT down 11%/12%/28% y/y; EBITDA margin at 19.7%). Good recovery in domestic auto/exports since Aug and healthy liquidity (~Rs2.5bn) were positives. The board approved a buyback of up to 0.75m shares at Rs400 each (record date: Nov 25). We are positive on Mayur on the brighter outlook: 1) swifter recovery in auto/exports; footwear to follow, 2) fast ramp-up at the PU plant as domestic OEMs would prefer to source locally after a 10% rise in the ADD and 3) robust export opportunity through customer additions. We maintain a Buy rating on the stock with a target of Rs356 (14x FY22e P/E), earlier Rs337. Good recovery, a healthy margin and better RoEs are keys to a re-rating.

**Q2,** a mixed-bag. Revenue/PBT/PAT were down 11%/12%/28% y/y; the EBITDA margin was up 283bps y/y to 19.7%. Recovery was swifter than anticipated. Lower other income impacted PBT. WC was in tight control with healthy cash position (~Rs2.5bn). A buyback of up to 0.75m shares @Rs400 each was approved; Nov 25 is fixed as the record date.

Good recovery in domestic auto/exports; footwear in slow lane. Per management, domestic auto and exports recovered swiftly since Aug while footwear, at ~60% recovery, is taking longer. Supply to VW and Mercedes SA could start by Q1 FY22 while approval from BMW is in an advanced stage.

**PU** plant – large import substitution, a game changer. While Covid-19 delayed the ramp-up, management sees strong demand for its PU products as domestic auto/footwear OEMs would prefer to source locally after a 10% increase in ADD on imports. Mayur's quality product and long relationship with these OEMs will throw up huge long-term opportunities.

**Maintaining a Buy.** As the concerns regarding the PU plant and exports are behind (reasons for a de-rating over the last two years), at ~10x FY22e P/E, we believe in good scope for a re-rating given improving prospects. Net-cash status and FCFs are other positives. **Risks:** Volatile RM prices, keen competition.

FY18	FY19	FY20	FY21e	FY22e
5,522	5,734	5,135	4,215	7,059
941	872	777	563	1,154
20.8	19.2	17.1	12.4	25.5
12.8	13.8	15.5	21.3	10.4
7.1	8.0	9.8	11.4	5.8
2.7	2.3	2.1	1.9	1.7
20.8	16.7	13.2	8.8	15.8
20.5	16.0	12.8	8.7	15.2
0.5	1.2	1.9	0.4	1.9
-0.4	-0.4	-0.3	-0.5	-0.4
	5,522 941 20.8 12.8 7.1 2.7 20.8 20.5 0.5	5,522     5,734       941     872       20.8     19.2       12.8     13.8       7.1     8.0       2.7     2.3       20.8     16.7       20.5     16.0       0.5     1.2	5,522         5,734         5,135           941         872         777           20.8         19.2         17.1           12.8         13.8         15.5           7.1         8.0         9.8           2.7         2.3         2.1           20.8         16.7         13.2           20.5         16.0         12.8           0.5         1.2         1.9	5,522         5,734         5,135         4,215           941         872         777         563           20.8         19.2         17.1         12.4           12.8         13.8         15.5         21.3           7.1         8.0         9.8         11.4           2.7         2.3         2.1         1.9           20.8         16.7         13.2         8.8           20.5         16.0         12.8         8.7           0.5         1.2         1.9         0.4

Rating: **Buy** Target Price: Rs356

Share Price: Rs265

Key data	MUNI IN / MAYU.BO
52-week high / low	Rs310 / 118
Sensex / Nifty	43594 / 12749
3-m average volume	\$0.5m
Market cap	Rs12bn / \$162m
Shares outstanding	45m

Shareholding pattern (%)	Sep'20	Jun'20	Mar'20
Promoters	61.5	61.5	61.5
- of which, Pledged	-	-	-
Free float	38.5	38.5	38.5
- Foreign institutions	5.1	7.1	7.6
- Domestic institutions	3.6	3.7	4.7
- Public	29.8	27.7	26.3

Estimates revision (%)	FY21e	FY22e
Sales	0	5
EBITDA	(9)	7
PAT	(14)	6



Source: Bloomberg

Ashish Poddar Research Analyst

Devanshi Kapadia Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

## **Quick Glance – Financials and Valuations (Stand.)**

Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
Net revenues	5,522	5,734	5,135	4,215	7.059
Growth (%)	15.8	3.8	-10.4	-17.9	67.5
Direct costs	3,240	3,516	3,060	2,528	4,235
SG&A	832	943	1,036	907	1,267
EBITDA	1,451	1,275	1,039	779	1,556
EBITDA margins (%)	26.3	22.2	20.2	18.5	22.1
- Depreciation	171	180	184	184	220
Other income	132	215	191	185	220
Interest expenses	14	8	17	23	8
PBT	1,398	1,301	1,029	758	1,548
Effective tax rate (%)	32.7	33.0	24.5	25.7	25.5
+ Associates / (Minorities)	-	-	-	-	-
Net income	941	872	777	563	1,154
Adjusted income	941	872	777	563	1,154
WANS	45	45	45	45	45
FDEPS (Rs / sh)	20.8	19.2	17.1	12.4	25.5
FDEPS growth (%)	15.4	(7.4)	(10.8)	(27.5)	104.9
Gross margins (%)	41.3	38.7	40.4	40.0	40.0

Fig 2 - Balance sheet (Rs m)									
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e				
Share capital	227	227	227	227	227				
Net worth	4,535	5,230	5,872	6,389	7,316				
Debt (incl. pref.)	19	192	261	261	261				
Minority interest	-	-	-	-	-				
DTL / (Assets)	77	66	40	35	30				
Capital employed	4,630	5,488	6,173	6,686	7,608				
Net tangible assets	1,311	1,241	1,508	1,724	1,904				
Net intangible assets	9	4	3	3	3				
Goodwill	-	-	-	-	-				
CWIP (tang. & intang.)	19	393	393	43	38				
Investments (strategic)	1	69	69	69	69				
Investments (financial)	1,562	1,869	1,652	2,852	2,952				
Current assets (ex cash)	2,187	2,481	2,902	2,105	3,233				
Cash	256	192	524	647	472				
Current liabilities	715	761	880	759	1,065				
Working capital	1,472	1,720	2,022	1,346	2,168				
Capital deployed	4,630	5,488	6,173	6,686	7,608				
Contingent liabilities	57	408	146	-	-				

Fig 3 – Cash-flow statement (Rs m)								
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e			
EBIT (excl. other income)	1,280	1,095	855	595	1,336			
+ Non-cash items	171	180	184	184	220			
Oper. prof. before WC	1,451	1,275	1,039	779	1,556			
- Incr. / (decr.) in WC	172	131	232	-686	812			
Others incl. taxes	457	557	350	233	433			
Operating cash-flow	821	587	457	1,232	312			
- Capex (tang. + intang.)	191	478	452	50	395			
Free cash-flow	631	109	6	1,182	-83			
Acquisitions								
- Div.(incl. buyback & taxes)	76	177	272	45	227			
+ Equity raised	-2	-	-	-	-			
+ Debt raised	-48	173	69	-	-			
- Fin investments	322	375	-217	1,200	100			
- Misc. (CFI + CFF)	129	(206)	(312)	(186)	(235)			
Net cash-flow	53	-64	332	123	-175			
Source: Company, Anand Rathi Research								

Fig 4 - Ratio analysis							
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e		
P/E (x)	12.8	13.8	15.5	21.3	10.4		
EV / EBITDA (x)	7.1	8.0	9.8	11.4	5.8		
EV / Sales (x)	1.9	1.8	2.0	2.1	1.3		
P/B (x)	2.7	2.3	2.1	1.9	1.7		
RoE (%)	20.8	16.7	13.2	8.8	15.8		
RoCE (%) - after tax	20.5	16.0	12.8	8.7	15.2		
Fixed asset T/O (x)	23.1	18.1	14.4	9.9	17.6		
DPS (Rs / sh)	1.4	3.3	5.0	1.0	5.0		
Dividend yield (%)	0.5	1.2	1.9	0.4	1.9		
Div. payout (%) - incl. DDT	6.7	16.9	29.2	8.0	19.6		
Net debt / equity (x)	-0.4	-0.4	-0.3	-0.5	-0.4		
Receivables (days)	88	76	99	75	75		
Inventory (days)	47	61	76	65	65		
Payables (days)	38	36	41	40	40		
CFO: PAT %	87.3	67.3	58.9	218.8	27.0		
Source: Company, Anand Rathi Research							

Fig 5 - Price movement





Fig 6 – Q2 FY21 revenue break-up (estimate)



% Q/Q

191

207

H1FY21

1,487

882

H1FY20

2,524

1,567

% Y/Y

(41)

(44)

% Y/Y

(11)


(14)


# **Financial Performance**


Fig 7 – Financial performance (standalone)									
(Rs m)	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21				
Income	1,242	1,246	1,394	381	1,106				
RM costs	777	732	760	217	666				
Employee expenses	75	78	90	78	83				
Other expenses	181	186	186	90	140				
EBITDA	209	250	358	(5)	217				


						\ /				\ /
Employee expenses	75	78	90	78	83	11	6	161	156	3
Other expenses	181	186	186	90	140	(23)	55	231	489	(53)
EBITDA	209	250	358	(5)	217	4	(4,863)	213	460	(54)
Depreciation	44	46	50	34	50	13	48	84	87	(4)
Finance costs	1	5	8	5	8	446	58	13	3	280
Other income	52	45	57	55	30	(41)	(45)	85	168	(49)
PBT	215	244	357	12	190	(12)	1,529	202	458	(56)
Tax	15	62	91	4	46	211	1,202	49	99	(50)
PAT	200	182	266	8	144	(28)	1,670	152	359	(58)
EPS	4.4	4.0	5.9	0.2	3.2	(28)	1,670	3.4	7.9	(58)
As % of income						bps y/y	bps q/q			bps y/y
Gross margins	37.4	41.2	45.5	43.0	39.8	238	(319)	40.6	37.9	271
Employee cost	6.0	6.2	6.4	20.5	7.5	146	(1,298)	10.8	6.2	462
Other expenses	14.6	14.9	13.3	23.8	12.7	(191)	(1,106)	15.5	19.4	(386)
EBITDA margins	16.8	20.1	25.7	(1.2)	19.7	283	2,085	14.3	18.2	(392)
PBT margins	17.3	19.6	25.6	3.1	17.2	(13)	1,410	13.6	21.3	(776)
Effective tax rate	6.8	25.4	25.5	30.1	24.1	1,722	(604)	24.4	21.6	277
PAT margins	16.1	14.6	19.1	2.1	13.0	(308)	1,089	10.2	14.2	(397)

Source: Company, Anand Rathi Research












Source: Company, Anand Rathi Research


Source: Company, Anand Rathi Research





Source: Company, Anand Rathi Research





Source: Company, Anand Rathi Research


## **Valuation**

While short-term growth challenges persist, we are keen on Mayur for its leading position in synthetic leather and FCF-generation ability even in a downturn. While most of its PVC capacities are already fully utilised, future growth depends on capacity addition. However, its foray into PU leather would bring additional revenues and support growth in coming years.

After returning to growth since Aug, management expects Q3 to be a strong quarter, driven by auto/exports. Footwear recovery is in the slow lane and is expected to increase only gradually. Intermittent lockdowns in Europe and other markets are a concern, though.

We continue to like Mayur for its leading position in artificial leather, brighter outlook due to good traction at the recently commissioned PU plant, talk of curbing imports of leather goods from China and robust export opportunities from customers added. At ~10x FY22e P/E, we maintain a Buy rating with a target of Rs356 (14x FY22e P/E), earlier Rs337. Good recovery, a healthy margin and better RoEs are keys to a rerating.

Fig 16 – Change in estimates									
	Original Estin	nates	Revised Estir	nates	Change	€ (%)			
(Rs m)	FY21e	FY22e	FY21e	FY22e	FY21e	FY22e			
Revenue	4,211	6,702	4,215	7,059	0	5			
EBITDA	854	1,452	779	1,556	(9)	7			
EBITDA margins %	20.3	21.7	18.5	22.1					
PAT	657	1,091	563	1,154	(14)	6			
EPS (Rs)	14.5	24.1	12.4	25.5	(14)	6			



#### Risks

Source: Anand Rathi Research


- Volatile raw-material prices. Release paper, knitted fabric and chemicals (PU/PVC resin) are important raw materials for Mayur. Though any fluctuations in raw material prices are fully/partially passed on to customers, short-term margins may be hit.
- Cut-throat competition. Mayur faces keen competition from Chinese products, especially in PU-coated fabric. Thus, competition may eat into its revenues and margins.

#### **Appendix**

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies
Rating and Target Price History (as of 12 November 2020)



#### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)							
	Buy	Hold	Sell				
Large Caps (>US\$1bn)	>15%	5-15%	<5%				
Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%				

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL,

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	

#### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2019. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.